BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Acute Ischemic Stroke readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Acute Ischemic Stroke
 \, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05065216-903@assetmemo.bio
DTSTAMP:20261121T005331Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rinvecalinase alfa: Phase 2/3 readout est. (NCT05065216)
DESCRIPTION:Rinvecalinase alfa\, phase 2/3\, Acute Ischemic Stroke.\nStudy:
  Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)\nEstimated primary com
 pletion: December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/rinvecalinase-alfa#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05065216
URL:https://assetmemo.bio/drug/rinvecalinase-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739160-11093@assetmemo.bio
DTSTAMP:20261121T005331Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:HRS-4029: Phase 2 readout est. (NCT07739160)
DESCRIPTION:HRS-4029\, phase 2\, Acute Ischemic Stroke.\nStudy: The Efficac
 y and Safety of HRS-4029 in Acute Ischemic Stroke Patients\nEstimated prim
 ary completion: April 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/hrs-4029#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07739160
URL:https://assetmemo.bio/drug/hrs-4029#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06853535-6104@assetmemo.bio
DTSTAMP:20261121T005331Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Brilinta (Ticagrelor): Phase 3 readout est. (NCT06853535)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 3\, Acute Ischemic Stroke.\nStudy
 : Precision Antiplatelet Therapy Guided by Platelet Aggregation Function i
 n Patients With Acute Ischemic STROKE\nEstimated primary completion: 30 Ju
 ne 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ticagrelor#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06853
 535
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392450-10318@assetmemo.bio
DTSTAMP:20261121T005331Z
DTSTART;VALUE=DATE:20271206
DTEND;VALUE=DATE:20271207
SUMMARY:Adzynma (Apadamtase alfa): Phase 2 readout est. (NCT07392450)
DESCRIPTION:Adzynma (Apadamtase alfa)\, phase 2\, Acute Ischemic Stroke.\nS
 tudy: A Study of TAK-755 in Adults With Acute Ischemic Stroke\nEstimated p
 rimary completion: 6 December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/apadamtase-alfa#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07392450
URL:https://assetmemo.bio/drug/apadamtase-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07844603-6104@assetmemo.bio
DTSTAMP:20261121T005331Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Brilinta (Ticagrelor): Phase 2 readout est. (NCT07844603)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 2\, Acute Ischemic Stroke.\nStudy
 : Combined Antiplatelet Strategy in Acute Ischemic Stroke Following Thromb
 ectomy and/or Intravenous Thrombolysis (CoPRIME)\nEstimated primary comple
 tion: 31 December 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/ticagrelor#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07844603
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
